- More than a quarter of large companies are adding new criteria for GLP-1 coverage this year or next, while 11% have dropped or plan to drop coverage for weight-loss use altogether, per Mercer data.
- Employers like Chevron are requiring workers to log weight monthly, track meals via app, or complete health coaching sessions to maintain coverage — new hoops that didn’t exist when the drugs first became a popular benefit.
- HCA Healthcare stopped covering GLP-1s for weight loss as of January after use on its employee plan surged 90% in 2025; Blue Cross Blue Shield of Massachusetts moved the benefit to an optional add-on after projecting costs near $1 billion this year.
- Globally, employer coverage of GLP-1s for weight loss has already fallen to 23% in 2026 from 30% in 2024, as commercial insurance coverage stalls at roughly 50% in the U.S., despite manufacturer discounts from Eli Lilly and Novo Nordisk.
What Happened?
Employer coverage of GLP-1 drugs like Ozempic and Wegovy for weight loss — once a fast-growing workplace benefit — is now in retreat. With roughly one in eight American adults now taking the drugs, costs have spiraled well beyond what many companies budgeted. HCA Healthcare, with more than 300,000 employees, cut weight-loss coverage entirely in January after GLP-1 use on its plan surged 90% in 2025. Blue Cross Blue Shield of Massachusetts shifted the benefit to an optional employer add-on, projecting its costs would hit nearly $1 billion this year — seven times what it spent in 2023 — without action. Others are adding new conditions: Chevron now requires employees to log their weight monthly, track meals on an app, and meet regularly with an online health coach in order to keep their coverage. A new Mercer survey finds over 25% of large employers are tightening criteria, while 11% are exiting weight-loss coverage altogether.
Why It Matters?
GLP-1 drugs have become one of the most coveted workplace benefits, with a recent NFP survey finding about 30% of workers would switch jobs to get coverage. That retention power is exactly why employers are reluctant to cut the benefit — but costs are forcing their hand. The debate within corporate America is real: some early adopters report that after 18 to 24 months of broad coverage, overall healthcare costs started declining as obesity-related conditions improved. An Aon study of 192,000 GLP-1 users found slower medical cost growth and fewer hospitalizations after 18 months. But current drug prices — ranging from $149 cash to $1,350 per month at list — remain too high for that math to reliably pencil out, especially as companies face double-digit increases in overall medical costs.
What’s Next?
Eli Lilly is attempting to work around the employer pullback with its new Employer Connect program, offering Zepbound at a discounted $449 per month and preparing to sell its weight-loss pill at $399 per month. Novo Nordisk is making similar pushes. But overall commercial coverage has stalled at roughly 50% in the U.S. and is declining globally. The longer-term outlook may hinge on whether lower-cost generic or compounded versions gain regulatory acceptance — or whether enough employers accumulate long-term data showing net savings to reverse the trend.
Source: The Wall Street Journal
